Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.
2.

Binding of Clostridium difficile toxin A to human milk secretory component.

Dallas SD, Rolfe RD.

J Med Microbiol. 1998 Oct;47(10):879-88.

PMID:
9788811
3.
4.

Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor.

Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, Gao N, Xu YL, Walker WA, LaMont JT.

J Clin Invest. 1992 Sep;90(3):822-9.

5.

Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Kelly CP, Pothoulakis C, Orellana J, LaMont JT.

Gastroenterology. 1992 Jan;102(1):35-40.

PMID:
1309359
7.

Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.

Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C.

Infect Immun. 1999 Jan;67(1):302-7.

8.

Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.

Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H.

J Med Microbiol. 2013 Sep;62(Pt 9):1394-404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.

PMID:
23518659
9.
10.

In vitro and in vivo neutralizing activity of human colostrum and milk against purified toxins A and B of Clostridium difficile.

Kim K, Pickering LK, DuPont HL, Sullivan N, Wilkins T.

J Infect Dis. 1984 Jul;150(1):57-62.

PMID:
6747345
11.
12.

Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization.

Siddiqui F, O'Connor JR, Nagaro K, Cheknis A, Sambol SP, Vedantam G, Gerding DN, Johnson S.

J Infect Dis. 2012 Jan 1;205(1):128-33. doi: 10.1093/infdis/jir688. Epub 2011 Nov 28.

PMID:
22124129
13.
14.

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.

Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC.

Vaccine. 2012 Jun 13;30(28):4249-58. doi: 10.1016/j.vaccine.2012.04.045. Epub 2012 Apr 23.

PMID:
22537987
15.

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.

Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD Jr.

Infect Immun. 2006 Nov;74(11):6339-47. Epub 2006 Sep 11.

16.

Purification and characterisation of intracellular toxin A of Clostridium difficile.

Meng XQ, Kamiya S, Yamakawa K, Ogura H, Nakamura S.

J Med Microbiol. 1993 Jan;38(1):69-73.

PMID:
8418298
17.

A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum.

Castagliuolo I, LaMont JT, Qiu B, Nikulasson ST, Pothoulakis C.

Gastroenterology. 1996 Aug;111(2):433-8.

PMID:
8690209
18.
19.

Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum.

Pothoulakis C, Kelly CP, Joshi MA, Gao N, O'Keane CJ, Castagliuolo I, Lamont JT.

Gastroenterology. 1993 Apr;104(4):1108-15.

PMID:
8462799
20.

The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.

Yang XQ, Zhao YG, Chen XQ, Jiang B, Sun DY.

BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.

Supplemental Content

Support Center